×
Adagene Net Profit Margin 2020-2025 | ADAG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Adagene net profit margin from 2020 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Adagene Net Profit Margin 2020-2025 | ADAG
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Adagene net profit margin from 2020 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.8B
Amgen (AMGN)
$154.9B
Gilead Sciences (GILD)
$140.2B
Vertex Pharmaceuticals (VRTX)
$100.3B
Bristol Myers Squibb (BMY)
$96B
GSK (GSK)
$80.8B
CSL (CSLLY)
$67.1B
Regeneron Pharmaceuticals (REGN)
$61.5B
Alnylam Pharmaceuticals (ALNY)
$58.5B
Argenex SE (ARGX)
$43.6B
Insmed (INSM)
$28.8B
BioNTech SE (BNTX)
$24B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$19.4B
Incyte (INCY)
$16.5B
Genmab (GNMSF)
$16.5B
Genmab (GMAB)
$16B
Illumina (ILMN)
$15.4B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.3B
Exelixis (EXEL)
$10.1B
Moderna (MRNA)
$9.4B
Verona Pharma American Depositary Share (VRNA)
$9.2B
Exact Sciences (EXAS)
$9B
Bio-Techne Corp (TECH)
$8.6B
Halozyme Therapeutics (HALO)
$8.6B
Guardant Health (GH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B